We use cookies to analyse website traffic, understand where our visitors are coming from, and show you personalised content about treatments and regulations.For more information, please visit our Privacy and Cookie Policy.
Choose which cookies you allow. Necessary cookies are always on because the site cannot work without them. For details, see our Privacy and Cookie Policy.
Strictly necessaryRequired for core site functionality such as security, logging in and your basic preferences. Always active.
AnalyticsHelp us understand how visitors use the site (e.g. Google Analytics) so we can improve it.
MarketingUsed to show you personalised content about treatments and regulations, and to contact you about your enquiries.
In a recent trial, 80% of patients with (MRD)-positive acute lymphoblastic leukemia (ALL) who were treated with a drug called Blincyto (blinatumomab) achieved a complete response.
Experts in novel medicines
